Published: Tue, June 05, 2018
Health Care | By Oscar Goodwin

Many breast cancer patients can skip chemo

Many breast cancer patients can skip chemo

The clinical trial followed over 10,000 women with hormone-receptor-positive, HER2-negative breast cancer, that had developed tumors under 5 cm (2 inches) in diameter, and which hadn't yet spread to the lymph nodes.

A leading oncologist said the findings will lead to a "fundamental change" in how the disease is treated.

Judy Perkins said she felt as if she had a second chance at life.

The team reports the case of a Florida woman named Judy Perkins, who was diagnosed in 2003 with breast cancer when she was still in her 30s.

These are the results from a single patient and much larger trials will be needed to confirm the findings.

"This new study really gives us good reliable data based on almost 7,000 patients, that if you have an intermediate risk score, you don't benefit from chemotherapy", said Dr. John Rimmer, Breast Cancer Surgeon.

Iran slams terrorist attack in Kabul
A suicide attack on Monday targeted a key religious gathering in Kabul in which clerics described such attacks as un-Islamic. The council also called for peace negotiations between the two sides - the first time they have issued such an appeal.


This trial of 10,273 women analysed cancers using a genetic test that is already widely available, including on the NHS.

These results provide assurance that getting gene tested is a valuable first step for patients with this type of breast cancer. Doctors know that most don't need it, but evidence is thin on who can forgo it.

The TAILORx study, led by the Montefiore Medical Centre in NY, found women older than 50 with this form of breast cancer and a score of up to 25 did not need chemotherapy. Clearly communicating research findings are important for helping patients make informed decisions about treatment and modifying risk.

Nine-year survival rates were 93.9% without chemotherapy and 93.8% with chemotherapy, the study found.

Chemotherapy may be avoided in about 70% of early-stage breast cancer patients, thus limiting chemotherapy to the 30% for whom it can be predicted to be beneficial, a study released on Sunday (3 June) shows.

A woman with advanced breast cancer which had spread around her body has been completely cleared of the disease by a groundbreaking therapy that harnessed the power of her immune system to fight the tumours.

China warns trade benefits at risk if US imposes tariffs
After a lull in tensions following China's May 19 pledge, the White House renewed its threat last week. The tariff threat may enhance Ross' leverage as he sits down in Beijing with his Chinese counterparts.


It saves lives, but side-effects of the toxic drugs range from vomiting, fatigue and infertility to permanent nerve pain. While trying treatment after treatment, she became a breast cancer advocate and went to California for training by Project Lead, a program run by the National Breast Cancer Coalition. That comprises about 85 percent of women with breast cancer in this age group, the researchers noted.

A United States woman with advanced breast cancer is healthy again after taking part in an experimental treatment, using her body's own immune system to wipe out the tumours. "To have your health professional tell you don't need chemo, there's one side glad you don't have to have it and the other wondering are we really taking care of my breast cancer", said Garner. They also have a score between 11 and 25 on the Oncotype DX Breast Recurrence Score test.

The researchers are "trying to find ways" to achieve more consistent outcomes, Goff said.

"Because this is a huge study". Now only about 60 percent of US patients who could potentially benefit from it are taking the gene test, he says.

Phyllis Laccetti, a participant in the TailorX breast cancer study, at her home in Ossining, NY.

In this latest study, researchers focused on the 69 percent of the clinical trial's participants who had mid-range test scores.

Supreme Court justices side with Colorado baker on same-sex wedding cake
The Associated Press reports that appeals in similar cases are pending. Last summer, the Supreme Court chose to take the case. In a highly anticipated decision, the U.S.


Alan Melcher, professor of translational immunotherapy at the Institute of Cancer Research in London, who was not involved in the study said: "The work shows that even cancers like breast cancer, which don't have many antigens, are amenable to this sort of treatment".

Like this: